Navigation Links
Edwards Lifesciences' Board Approves New $250 Million Share Repurchase Program
Date:7/11/2008

IRVINE, Calif., July 11 /PRNewswire-FirstCall/ -- Edwards Lifesciences Corporation (NYSE: EW), a world leader in products and technologies to treat advanced cardiovascular disease, announced today that its board of directors has authorized a new share repurchase program to acquire up to $250 million of the company's outstanding common shares. Edwards recently completed a $250 million share repurchase program that its board of directors approved in September 2007.

"This new program reaffirms the confidence we have in our future growth prospects, and provides us with an opportunity to continue to increase shareholder value," said Michael A. Mussallem, Edwards Lifesciences' chairman and CEO.

Approximately 2.7 million shares were issued in June 2008 in response to the call for redemption by the company of its $150 million convertible debenture. During the second quarter of 2008, the company repurchased 2.3 million shares for approximately $135 million, partially offsetting the issuance of these shares.

During the first half of 2008, Edwards repurchased a total of 4.6 million shares for approximately $235 million. As of June 30, 2008, the company had approximately 56.2 million shares of common stock outstanding.

The company may repurchase shares in the open market or in privately negotiated transactions. The timing and extent of any repurchase will depend upon market conditions, corporate requirements and other factors.

About Edwards Lifesciences

Edwards Lifesciences is the global leader in the science of heart valves and hemodynamic monitoring. Headquartered in Irvine, Calif., Edwards treats advanced cardiovascular disease with its market-leading heart valve therapies, and critical care and vascular technologies. In 2008, Edwards celebrates 50 years of partnering with clinicians to develop life-saving innovations. The company's global brands, which are sold in approximately 100 countries, include CardioVations, Carpentier-Edwards, Cosgrove-Edwards, FloTrac, Fogarty, PERIMOUNT Magna and Swan-Ganz. Additional company information can be found at http://www.edwards.com.

This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements include, but are not limited to, the company's ability to promptly respond to the FDA's questions and receive an SFA indication by the end of the year. Forward-looking statements are based on estimates and assumptions made by management of the company and are believed to be reasonable, though they are inherently uncertain and difficult to predict.

Forward-looking statements involve risks and uncertainties that could cause actual results or experience to differ materially from that expressed or implied by the forward-looking statements. Factors that could cause actual results or experience to differ materially from that expressed or implied by the forward-looking statements are detailed in the company's filings with the Securities and Exchange Commission including its Annual Report on Form 10-K for the year ended December 31, 2007.

Edwards is a trademark of Edwards Lifesciences Corporation. Edwards Lifesciences, the stylized E logo, CardioVations, Carpentier-Edwards, Cosgrove-Edwards, FloTrac, Fogarty, PERIMOUNT Magna, and Swan-Ganz are trademarks of Edwards Lifesciences Corporation and are registered in the United States Patent and Trademark Office.


'/>"/>
SOURCE Edwards Lifesciences Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Edwards Lifesciences to Present at the Goldman Sachs 29th Annual Global Healthcare Conference
2. Edwards Lifesciences Receives Additional Questions From the FDA About the LifeStent Product Line
3. Aflac to be Primary Sponsor of Carl Edwards and the No. 99 Ford Fusion
4. Edwards Lifesciences Announces Retirement of Director Vernon Loucks
5. Edwards Lifesciences to Host Earnings Conference Call on April 22, 2008
6. Optimal Readings Appoints Operations Veteran Rita Edwards as SVP Clinical Operations
7. Edwards Lifesciences Chairman and CEO Adopts New 10b5-1 Stock Trading Plan to Replace Recently Expired Plan
8. Edwards Lifesciences to Present at the Citi 5th Annual Small and Mid-Cap Conference
9. Edwards Lifesciences to Present at the Cowen and Company Annual Healthcare Conference
10. Edwards Lifesciences Initiates Patent Infringement Litigation Against CoreValve in the U.S.
11. Edwards Lifesciences Reports Strong Fourth Quarter Sales
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2017)... Philadelphia, PA (PRWEB) , ... March 30, 2017 ... ... Wharton School is expanding its educational offerings of corporate finance programs to address ... a new program, will help executives increase their knowledge of sophisticated corporate finance ...
(Date:3/30/2017)... ... March 30, 2017 , ... ... live audio conference “ Preventing Hospital Readmissions Through Discharge Planning ” with noted ... 1:00 pm ET. This conference discusses strategies to prevent readmissions in light of ...
(Date:3/29/2017)... ... March 29, 2017 , ... In the United States alone, up ... year develop other types of metastatic brain tumors(3). Though most meningiomas are benign, metastatic ... focus on finding more effective treatment options, the San Diego Gamma Knife Center ...
(Date:3/29/2017)... MD (PRWEB) , ... March 30, 2017 , ... CHARM ... Charm City Run has announced that Mercy Medical Center will serve as the official ... the Mid-Atlantic region. On Sunday, June 25, 2017, thousands of women will walk or ...
(Date:3/29/2017)... ... 2017 , ... Wells Pharmacy Network, a proud A4M Platinum ... World Congress, in Hollywood Florida April 6-8, 2017. , Ben David, CEO of ... in the training of physicians, scientists, and members of the public on anti-aging ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... Mar. 29, 2017 Research and Markets ... Market Size & Forecast By Type (Insource IONM, Outsource IONM), ... report to their offering. ... The global Intraoperative Neuromonitoring (IONM) market ... intraoperative neuromonitoring market is anticipated to witness significant growth in ...
(Date:3/29/2017)... Research and Markets has announced the addition of the "Global ... ... aesthetic devices market to grow at a CAGR of 8.12% during ... Devices Market 2017-2021, has been prepared based on an in-depth market ... landscape and its growth prospects over the coming years. The report ...
(Date:3/29/2017)... 29, 2017 Avelas Biosciences, Inc., a clinical stage oncology-focused ... today announced that Carmine N. Stengone , president and chief ... Needham & Company 16 th Annual Healthcare Conference on Wednesday, ... the Westin Grand Central Hotel in New York City ... ...
Breaking Medicine Technology: